JP2004504260A5 - - Google Patents

Download PDF

Info

Publication number
JP2004504260A5
JP2004504260A5 JP2000617916A JP2000617916A JP2004504260A5 JP 2004504260 A5 JP2004504260 A5 JP 2004504260A5 JP 2000617916 A JP2000617916 A JP 2000617916A JP 2000617916 A JP2000617916 A JP 2000617916A JP 2004504260 A5 JP2004504260 A5 JP 2004504260A5
Authority
JP
Japan
Prior art keywords
antigenic composition
composition according
monophosphoryl lipid
lymphokine
cytokine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000617916A
Other languages
English (en)
Japanese (ja)
Other versions
JP4974414B2 (ja
JP2004504260A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/013156 external-priority patent/WO2000069456A2/en
Publication of JP2004504260A publication Critical patent/JP2004504260A/ja
Publication of JP2004504260A5 publication Critical patent/JP2004504260A5/ja
Application granted granted Critical
Publication of JP4974414B2 publication Critical patent/JP4974414B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000617916A 1999-05-13 2000-05-12 アジュバント混合製剤 Expired - Fee Related JP4974414B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13396399P 1999-05-13 1999-05-13
US60/133,963 1999-05-13
PCT/US2000/013156 WO2000069456A2 (en) 1999-05-13 2000-05-12 Adjuvant combination formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011171095A Division JP5230780B2 (ja) 1999-05-13 2011-08-04 アジュバント混合製剤

Publications (3)

Publication Number Publication Date
JP2004504260A JP2004504260A (ja) 2004-02-12
JP2004504260A5 true JP2004504260A5 (https=) 2007-07-05
JP4974414B2 JP4974414B2 (ja) 2012-07-11

Family

ID=22461127

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000617916A Expired - Fee Related JP4974414B2 (ja) 1999-05-13 2000-05-12 アジュバント混合製剤
JP2011171095A Expired - Fee Related JP5230780B2 (ja) 1999-05-13 2011-08-04 アジュバント混合製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011171095A Expired - Fee Related JP5230780B2 (ja) 1999-05-13 2011-08-04 アジュバント混合製剤

Country Status (28)

Country Link
US (2) US7611721B1 (https=)
EP (1) EP1178825B1 (https=)
JP (2) JP4974414B2 (https=)
KR (1) KR100863367B1 (https=)
CN (1) CN1192799C (https=)
AT (1) ATE516046T1 (https=)
AU (1) AU781469B2 (https=)
BG (1) BG106094A (https=)
BR (1) BR0010539A (https=)
CA (2) CA2767116A1 (https=)
CZ (1) CZ20013916A3 (https=)
EA (1) EA006233B1 (https=)
EE (1) EE200100597A (https=)
ES (1) ES2367625T3 (https=)
GE (1) GEP20053446B (https=)
HR (1) HRP20010839A2 (https=)
HU (1) HUP0201220A3 (https=)
ID (1) ID30407A (https=)
IL (2) IL146382A0 (https=)
IS (1) IS6156A (https=)
MX (1) MXPA01011499A (https=)
NO (1) NO20015523L (https=)
NZ (1) NZ515322A (https=)
PL (1) PL352312A1 (https=)
SK (1) SK16022001A3 (https=)
TR (1) TR200103266T2 (https=)
UA (1) UA76406C2 (https=)
WO (1) WO2000069456A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
ID30407A (id) 1999-05-13 2001-11-29 American Cyanamid Co Formulasi-formulasi kombinasi bahan penambah
EP1333858B8 (en) 2000-11-07 2006-06-14 Immunovaccine Technologies Inc. Vaccines with enhanced immune response and methods for their preparation
HUP0600589A2 (en) 2000-11-10 2006-11-28 Wyeth Corp Adjuvant combination formulations
CA2700808C (en) 2007-09-27 2017-11-14 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
HUE035406T2 (en) * 2007-10-08 2018-05-02 Intrexon Corp Engineered dendritic cells and uses for the treatment of cancer
ES2524699T3 (es) 2008-06-05 2014-12-11 Immunovaccine Technologies Inc. Composiciones que comprenden liposomas, un antígeno, un polinucleótido y un vehículo que comprende una fase continua de una sustancia hidrófoba
EP2550362B1 (en) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
GB201113570D0 (en) * 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
JP6240077B2 (ja) 2011-10-06 2017-11-29 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． Ｔｌｒ２を活性化するか、またはその活性を増加させるアジュバントを含むリポソーム組成物およびその使用
RU2496149C1 (ru) * 2012-06-19 2013-10-20 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" (ФБУН ГНЦ ВБ "Вектор") Способ оценки противооспенной активности лечебно-профилактических препаратов
US10669528B2 (en) 2015-06-25 2020-06-02 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
WO2017161001A1 (en) 2016-03-15 2017-09-21 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US6294322B1 (en) 1988-01-26 2001-09-25 The United States Of America As Represented By The Department Of Health And Human Services Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1
US5939074A (en) 1986-12-30 1999-08-17 The United States Of America As Represented By The Department Of Health And Human Services Multideterminant peptide antigens
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5993819A (en) 1987-09-08 1999-11-30 Duke University Synthetic vaccine for protection against human immunodeficiency virus infection
US5013548A (en) 1987-09-08 1991-05-07 Duke University Production of antibodies to HIV
US5019387A (en) 1987-09-08 1991-05-28 Duke University Production of antibodies to HIV
US5223254A (en) 1987-09-29 1993-06-29 Praxis Biologics, Inc. Respiratory syncytial virus: vaccines
CA1340506C (en) * 1987-11-24 1999-04-20 Nicholas H. Carbonetti Production of gonorrheal pi proteins and vaccines
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
CA2441636A1 (en) 1988-11-10 1990-05-10 The Wistar Institute Of Anatomy And Biology Natural killer stimulatory factor
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
DE3934366A1 (de) 1989-10-14 1991-04-18 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum
ATE153534T1 (de) 1990-04-27 1997-06-15 John Mcmichael Verfahren und zusammensetzung zur behandlung von erkrankungen des zns hervorgerufen durch abnormales beta-amyloid-protein
SE502569C2 (sv) * 1991-05-31 1995-11-13 British Tech Group Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit
JPH07502729A (ja) 1991-12-02 1995-03-23 ボード・オヴ・リージェンツ，ザ・ユニヴァーシティ・オヴ・テキサス・システム 免疫応答または抗感染応答を誘発するための方法と組成物
US6037135A (en) 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
MX9304089A (es) 1992-07-08 1994-01-31 Schering Corp Uso de gm-csf como una vacuna adyuvante.
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
ATE157882T1 (de) 1993-03-23 1997-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
US5637480A (en) 1993-05-12 1997-06-10 Genetics Institute, Inc. DNA molecules encoding bone morphogenetic protein-10
EP0705109B2 (en) * 1993-05-25 2004-01-02 American Cyanamid Company Adjuvants for vaccines against respiratory syncytial virus
US5830877A (en) 1993-08-26 1998-11-03 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
ATE221786T1 (de) 1994-04-29 2002-08-15 Univ Duke Synthetischer impfstoff zum schutz gegen infektionen mit dem menschlichen immunschwächevirus
AUPM543894A0 (en) 1994-05-04 1994-05-26 Commonwealth Scientific And Industrial Research Organisation An adjuvant
AU3735095A (en) 1994-09-30 1996-04-26 Ludwig Institute For Cancer Research Compositions containing a p53 derived protein or peptide, an adjuvant, and interleukin-12 and uses thereof
PT784486E (pt) 1994-10-05 2006-07-31 Univ Vanderbilt Inerleucina-12 como um adjuvante para vacinas contra paramyxoviridae
US5955087A (en) * 1995-02-24 1999-09-21 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
US6613337B1 (en) 1997-02-12 2003-09-02 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
HUP9901039A2 (hu) 1996-02-01 1999-07-28 North American Vaccine, Inc. Neisseria meningitidis B-csoportba tartozó külső-membrán-fehérjéjének (MB3) expressziója élesztőben, továbbá vakcinák
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US5762943A (en) * 1996-05-14 1998-06-09 Ribi Immunochem Research, Inc. Methods of treating type I hypersensitivity using monophosphoryl lipid A
AU724743B2 (en) 1996-05-31 2000-09-28 Genetics Institute, Llc IL-12 as an adjuvant for Bordetella Pertussis vaccines
US6024965A (en) 1996-10-18 2000-02-15 Erasums University Rotterdam Induction of REV and TAT specific cytotoxic T-cells for prevention and treatment of human immunodeficiency virus (HIV) infection
KR100780158B1 (ko) * 1996-10-23 2007-11-27 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 면역 치료법 및 개량 백신
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6797276B1 (en) * 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US6350456B1 (en) * 1997-03-13 2002-02-26 Corixa Corporation Compositions and methods for the prevention and treatment of M. tuberculosis infection
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
WO1998056415A1 (en) 1997-06-11 1998-12-17 Aquila Biopharmaceuticals, Inc. Purified saponins as oral adjuvants
GB9711990D0 (en) * 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9712347D0 (en) * 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
EP1006999A2 (en) 1997-07-08 2000-06-14 Chiron Corporation Use of submicron oil-in-water emulsions with dna vaccines
IS4518A (is) 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
BR9907885A (pt) 1998-02-12 2000-11-14 American Cyanamid Co Composição de vacina, processo para fazer surgir uma resposta imune a um antìgeno de vìrus sincicial respiratório, e, composição imunogênica
WO1999040938A2 (en) 1998-02-12 1999-08-19 American Cyanamid Company Vaccines comprising interleukin-12 and herpes simplex viral antigen
ATE356630T1 (de) 1998-04-03 2007-04-15 Univ Iowa Res Found Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
GB9907860D0 (en) 1999-04-07 1999-06-02 Smithkline Beecham Biolog Novel compounds
ID30407A (id) 1999-05-13 2001-11-29 American Cyanamid Co Formulasi-formulasi kombinasi bahan penambah

Similar Documents

Publication Publication Date Title
US7867480B1 (en) Non-invasive vaccination through the skin
KR100399258B1 (ko) 비독성경구용어쥬번트로써효과적인장독소돌연변이체
US7504107B2 (en) Methods of priming the immunogenic activity of vaccines useful for eliciting a protective immune response
JP2004504260A5 (https=)
JPH04506662A (ja) 接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー
HK1030363B (en) Noninvasive vaccination through the skin
JP2003507341A5 (https=)
WO2000044349A9 (en) Non-invasive vaccination through the skin
JPH04506663A (ja) インターロイキン含有安定ワクチン組成物
Villacres-Eriksson et al. IMMUNOMODULATION BYQUILLAJA SAPONARIAADJUVANT FORMULATIONS: IN VIVO STIMULATION OF INTERLEUKIN 12 AND ITS EFFECTS ON THE ANTIBODY RESPONSE
KR20030015288A (ko) 보조제 배합물로서의 큐에스-21 및 아이엘-12
CA2372181A1 (en) Adjuvant combination formulations
JP2002526420A (ja) 脊椎動物における実質的に無毒で生物学的に活性な粘膜アジュバント
JPH05504756A (ja) 免疫刺激性を有する組成物と、そのヒトと獣医学用医薬への応用
EP0563254A1 (en) APPLICATION OF IL-4 TO INCREASE THE IMMUNE RESPONSE TO IMMUNOGENES IN VACCINE SUBSTANCES.
EP1768696B1 (en) Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus
CN1161154C (zh) 用于疫苗的免疫增强制剂
JP2008526985A (ja) 粘膜ワクチンの送達のためのペプチド
NZ250555A (en) Vaccine with enhanced immunogenicity by inclusion of a cytokine
JPH05505799A (ja) 感染性抗原チャレンジに対する免疫応答促進のためのｉｌ―４の使用
KR20240044461A (ko) 면역 조절을 위한 치은 틈새에서의 접합 상피의 표적화
JP2004523483A (ja) アジュバントの組合せ製剤
Alving et al. Design and selection of vaccine adjuvants: principles and practice
WO2023145749A1 (ja) 免疫賦活剤
JP2001521908A (ja) ワクチンアジュバントとして有用な封入された免疫調節物質